| Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs Y Xiao, J Wang, LY Zhao, X Chen, G Zheng, X Zhang, D Liao Chemical Communications 56 (68), 9866-9869, 2020 | 78 | 2020 |
| Piperlongumine (PL) conjugates induce targeted protein degradation J Pei, Y Xiao, X Liu, W Hu, A Sobh, Y Yuan, S Zhou, N Hua, ... Cell Chemical Biology 30 (2), 203-213, 2023 | 35* | 2023 |
| Phosphodiesters as GPR84 antagonists for the treatment of ulcerative colitis LH Chen, Q Zhang, YF Xiao, YC Fang, X Xie, FJ Nan Journal of Medicinal Chemistry 65 (5), 3991-4006, 2022 | 16 | 2022 |
| Sulfuretin protects hepatic cells through regulation of ROS levels and autophagic flux Y Lu, Y Xiao, Y Li, J Li, F Nan, J Li Acta Pharmacologica Sinica 40 (7), 908-918, 2019 | 16 | 2019 |
| Recent advances in small molecular modulators targeting histone deacetylase 6 Y Xiao, X Zhang Future Drug Discovery 2 (4), FDD53, 2020 | 15 | 2020 |
| HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation Y Xiao, S Hale, N Awasthee, C Meng, X Zhang, Y Liu, H Ding, Z Huo, D Lv, ... Cell Chemical Biology, 2023 | 3* | 2023 |
| Targeting intracellular proteins with cell type-specific functions for cancer immunotherapy ME Carelock, RP Master, MC Kim, Z Jin, L Wang, CK Maharjan, N Hua, ... Life Medicine 2 (3), lnad019, 2023 | 3 | 2023 |
| Discovery of hydrazide-based HDAC8 selective PROTACs Y Xiao, Y Liu, N Awasthee, C Meng, M He, S Hale, R Karki, Z Lin, R Kridel, ... Cancer Research 84 (6_Supplement), 3236-3236, 2024 | | 2024 |
| PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy L Wang, Y Xiao, Y Luo, RP Master, J Mo, MC Kim, Y Liu, CK Maharjan, ... Journal of Experimental Medicine 221 (3), e20231519, 2024 | | 2024 |
| Unleashing the Power of NR4A1 Degradation as a Novel Strategy for Cancer Immunotherapy L Wang, Y Xiao, Y Luo, RP Master, J Mo, MC Kim, Y Liu, UM Patel, X Li, ... bioRxiv, 2023 | | 2023 |
| DISCOVERY OF PIPERLONGUMINE AS A NOVEL E3 LIGASE LIGAND WH Daohong Zhou, Guangrong Zheng, Yaxia Yuan, Yufeng Xiao, Dongwen Lv, Jing ... WO Patent WO2023114455A1, 2023 | | 2023 |
| Benzoylhydrazide-derived hdac degraders as therapeutics for treating cancer and other human diseases D Liao, X Yufeng, X Zhang, G Zheng US Patent US2023181746A1, 2023 | | 2023 |
| Proteolysis-targeting chimera against NR4A1 for cancer immunotherapy L Wang, Y Xiao, R Master, Y Luo, G Zheng, D Zhou, W Zhang The Journal of Immunology 210 (1_Supplement), 245.07-245.07, 2023 | | 2023 |
| Abstract LB002: Extracellular vesicle loading of proteolysis targeting chimeras for targeted therapeutic delivery N Erwin, X Pan, N Awasthee, Y Xiao, G Zheng, D Liao, M He Cancer Research 83 (8_Supplement), LB002-LB002, 2023 | | 2023 |
| Developing a PROTAC-based NR4A1 degrader for melanoma cancer therapy R Master, Y Luo, Y Xiao, D Zhou, L Wang, G Zheng, W Zhang Cancer Research 83 (7_Supplement), 4451-4451, 2023 | | 2023 |
| MODULATORS OF NUCLEAR RECEPTOR SUBFAMILY 4 GROUP A MEMBER 1 (NR4A1) AND USES THEREOF W Zhang, G Zheng, D Zhou, Y Xiao, L Wang WO Patent WO2022072094A2, 2022 | | 2022 |
| GPR84 receptor antagonist and use thereof F Nan, X Xie, C Linhai, Q Zhang, X Yufeng, H Yang US Patent 11,098,071, 2021 | | 2021 |
| Application of biphenyl phosphate compound as GPR84 antagonist F Nan, X Xie, Y Xiao, Q Zhang, L Chen CN Patent CN110,680,823 B, 2020 | | 2020 |
